SCHEMBL7075181

SCHEMBL7075181

CCOC(=O)C(C)c1nc2c([nH]1)CCN(C(=O)OCc1ccccc1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.47
GABRA5 P31644 1/20 0.44
DHFR P00374 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
LMNA P02545 1/20 0.42
PABPC1 P11940 1/20 0.42
ATM Q13315 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TMEM97 Q5BJF2 7/20 0.42
SIGMAR1 Q99720 7/20 0.42
HTR1A P08908 1/20 0.42
CHRM5 P08912 1/20 0.42
SLC6A2 P23975 1/20 0.42
HRH2 P25021 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR1E P28566 1/20 0.42
HRH1 P35367 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7075795 0.83 KDR (0.49) KDRGABRA5DHFRLMNAPABPC1
SCHEMBL7073122 0.82 KDR (0.47) KDRGABRA5DHFRPTGDR2TMEM97
SCHEMBL21496813 0.79 KDR (0.52) KDRGABRA5DHFRPTGDR2SMN1; SMN2
SCHEMBL7067767 0.77 NR1H4 (0.42) KDRGABRA5DHFRTMEM97SIGMAR1
SCHEMBL7068327 0.74 KDR (0.41) KDRGABRA5DHFRTMEM97SIGMAR1
SCHEMBL7479335 0.73 TMEM97 (0.46) PTGDR2SMN1; SMN2TMEM97SIGMAR1HTR1A
SCHEMBL31607740 0.73 TMEM97 (0.53) KDRDHFRLMNAPABPC1ATM
SCHEMBL6421762 0.73 KDR (0.49) KDRGABRA5DHFRPTGDR2SMN1; SMN2
SCHEMBL21388656 0.72 ALDH1A1 (0.41) KDRATMHTR2C
SCHEMBL504656 0.72 DHFR (0.46) KDRDHFRPTGDR2SMN1; SMN2TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed
EP-1019382-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS, INC. (US) 2000-07-19 EP disclosed
WO-1998045275-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS CORPORATION (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 KDR 3600/4885GABRA5 4741/4885DHFR 1686/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 KDR 2760/4885GABRA5 2750/4885DHFR 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.